

Claims:

1. Use of a P2Y₁₂ receptor antagonist, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of a disease, wherein the disease is selected from acute arterial thromboses and acute venous thromboses; wherein the P2Y₁₂ receptor antagonist is 4-((R)-2-[[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester; and wherein the P2Y₁₂ receptor antagonist is administered and/or is to be administered to a patient by intradermal or subcutaneous administration.
2. The use according to claim 1, wherein the disease is selected from acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack.
3. The use according to any one of claims 1 or 2, wherein the P2Y₁₂ receptor antagonist is administered and/or is to be administered prior to hospitalization.
4. The use according to claim 3, wherein the P2Y₁₂ receptor antagonist is administered and/or is to be administered by patient self-administration.
5. Use of a P2Y₁₂ receptor antagonist, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the emergency treatment of suspected acute coronary syndromes by patient self-administration prior to hospitalization; wherein the P2Y₁₂ receptor antagonist is 4-((R)-2-[[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester; and wherein the P2Y₁₂ receptor antagonist is administered and/or is to be administered to a patient by intradermal or subcutaneous administration.
6. The use according to any one of claims 1 to 5, wherein the P2Y₁₂ receptor antagonist is to be administered and/or is to be administered to a patient by subcutaneous administration.
7. The use according to any one of claims 1 to 6, wherein the amount of 4-((R)-2-[[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester that is administered and/or is to be administered is comprised between 1 mg and 75 mg per administration.
8. The use according to any one of claims 1 to 7, wherein the P2Y₁₂ receptor antagonist is administered and/or is to be administered in a bolus injection.

9. The use according to any one of claims 1 to 8, wherein an inhibition of platelet aggregation of at least 75% is reached within 30 min after onset of administration of the P2Y₁₂ receptor antagonist in at least 80% of the patients.
- 5 10. Use of a pharmaceutical composition comprising, as active principle, the P2Y₁₂ receptor antagonist 4-((R)-2-[[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use according to any one of claims 1 to 9, wherein the pharmaceutical composition is administered and/or is to be administered to a patient by
10 subcutaneous administration and wherein the pharmaceutical composition further comprises at least one therapeutically inert excipient.
11. Use of 4-((R)-2-[[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for
15 the treatment of a disease, wherein the disease is selected from acute coronary syndromes, myocardial infarction, peripheral ischaemia, amaurosis, sudden cardiac death, ischaemic stroke and transient ischaemic attack, and wherein the medicament is administered and/or is to be administered to a patient by subcutaneous administration.
- 20 12. Use of the P2Y₁₂ receptor antagonist 4-((R)-2-[[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino]-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the emergency treatment of suspected acute coronary syndromes by patient self-administration prior to hospitalization;
25 wherein the P2Y₁₂ receptor antagonist is to be administered to a patient by subcutaneous administration.